Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious conditions such as dementia and stroke, a new study has indicated. The research ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.

SAN ANTONIO — Tirzepatide demonstrated long-term weight-loss benefits and prevention of diabetes progression in patients with obesity and prediabetes, but only so long as they continued the ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year ...

GLP-1 receptor agonists like semaglutide have demonstrated benefits in slowing the progression of kidney disease in patients with diabetes. Tirzepatide may have similar advantages.

Changes in A1c and body weight were evaluated. TAKEAWAY: Tirzepatide was associated with a 42% lower risk for all-cause mortality than GLP-1 RAs (adjusted hazard ratio, 0.58; 95% CI, 0.45-0.75).